TWI BIOTECHNOLOGY, INC.

Highlights TWi Biotechnology, Inc.

Equities

6610

TW0006610009

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
15.15 ^TWD	-1.94%		+10.99%	+8.21%

04-09	TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-13	CI
TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)	23-06-02	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-14	CI
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203	21-01-06	CI
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-12	CI
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA	20-05-07	CI
Twi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-09	CI
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy	18-11-15	CI
TWi Biotechnology, Inc. Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	18-10-20	CI
TWi Biotechnology, Inc. Announces Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	18-02-26	CI
TWi Biotechnology Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment	16-06-27	CI
TWi Biotechnology, Inc. Enters Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals	15-12-22	CI
TWi Biotechnology, Inc. Completes Multinational Phase II Dose-Ranging Study of AC-201	12-08-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer